WASHINGTON - A trio of new studies published in JAMA Internal Medicine on Tuesday examining the efficacy of an arthritis drug against COVID-19 showed inconsistent results.
Of the three new studies, the largest was led by the Harvard-affiliated Brigham and Women's Hospital in the United States on more than 4,000 critically ill COVID-19 patients. There were also key differences in the patient demographics among those who received tocilizumab -- which the authors tried to control for using statistical methods -- but the risk of confounding factors remains.
The French trial looked at about 130 patients who weren't critically ill. The risk of death or progression to ventilators decreased in those on the drug by two weeks, but after 28 days mortality outcomes were similar. The US National Institutes of Health currently does not recommend tocilizumab for use against COVID-19 outside of clinical trials, and Tuesday's results will unlikely change that.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ANCALERTS - 🏆 26. / 50 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: CNN Philippines - 🏆 13. / 63 Read more »
Source: gmanetwork - 🏆 12. / 63 Read more »
Source: gmanetwork - 🏆 12. / 63 Read more »
Source: rapplerdotcom - 🏆 4. / 86 Read more »